Skip to content
HowShorted

TG THERAPEUTICS, INC. short interest in 2023

In 2023, TG THERAPEUTICS, INC.'s disclosed short interest ran from 15.52% of shares outstanding on 13 Jan 2023 to 21.02% on 29 Dec 2023, a change of +5.50 percentage points. The year's high was 24.65% on 13 Oct 2023 and its low 14.57% on 15 May 2023, averaging 18.79% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.02 days on 13 Oct 2023. Full history: TG THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TG THERAPEUTICS, INC. in 2023

2023 in figures

Start of year
15.52% (13 Jan 2023)
End of year
21.02% (29 Dec 2023)
Change
+5.50 pp
High
24.65% (13 Oct 2023)
Low
14.57% (15 May 2023)
Average
18.79%
Highest days to cover
10.02 (13 Oct 2023)
SEC filings marked
8

Every report in 2023

TG THERAPEUTICS, INC. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 202315.52%3.14
31 Jan 202316.14%5.74
15 Feb 202316.81%5.24
28 Feb 202317.87%6.73results (8-K)
15 Mar 202318.34%6.9410-K filed
31 Mar 202319.55%8.54
14 Apr 202318.89%4.66
28 Apr 202317.62%7.36
15 May 202314.57%3.47results (8-K), 10-Q filed
31 May 202315.01%7.31
15 Jun 202315.05%6.75
30 Jun 202315.11%6.57
14 Jul 202314.95%5.45
31 Jul 202315.45%6.47
15 Aug 202318.23%2.54results (8-K), 10-Q filed
31 Aug 202318.52%8.95
15 Sep 202319.55%6.65
29 Sep 202321.53%8.96
13 Oct 202324.65%10.02
31 Oct 202324.52%7.01
15 Nov 202324.18%3.31results (8-K), 10-Q filed
30 Nov 202323.72%8.68
15 Dec 202324.12%6.47
29 Dec 202321.02%6.52

See also: TG THERAPEUTICS, INC.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.